<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/89567AAF-2DC2-44FC-9DC1-58C569EB26D2"><gtr:id>89567AAF-2DC2-44FC-9DC1-58C569EB26D2</gtr:id><gtr:name>Iron Horse Diagnostics, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BB35394B-CAE4-447B-987C-58186408481A"><gtr:id>BB35394B-CAE4-447B-987C-58186408481A</gtr:id><gtr:name>Stony Brook University</gtr:name><gtr:address><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FA143EC1-E637-4E0C-80ED-0EA8ED214038"><gtr:id>FA143EC1-E637-4E0C-80ED-0EA8ED214038</gtr:id><gtr:name>University of Leuven</gtr:name><gtr:address><gtr:line1>Oude Markt 13</gtr:line1><gtr:line2>Box 5005</gtr:line2><gtr:region>outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B"><gtr:id>22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B</gtr:id><gtr:name>University of Ulm</gtr:name><gtr:address><gtr:line1>Albert Einstein Allee 5</gtr:line1><gtr:line4>Ulm</gtr:line4><gtr:postCode>89081</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AB307619-D4FA-427E-A042-09DBEBA84669"><gtr:id>AB307619-D4FA-427E-A042-09DBEBA84669</gtr:id><gtr:name>Swansea University</gtr:name><gtr:address><gtr:line1>Singleton Park</gtr:line1><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BAF7118-A7CB-4385-903E-255DD6F6908A"><gtr:id>7BAF7118-A7CB-4385-903E-255DD6F6908A</gtr:id><gtr:name>Friedrich Schiller University Jena (FSU)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F53AAC5E-F39C-4570-AD7E-0B995E0F8FD2"><gtr:id>F53AAC5E-F39C-4570-AD7E-0B995E0F8FD2</gtr:id><gtr:name>University of Miami</gtr:name><gtr:address><gtr:line1>1204 Dickinson Drive</gtr:line1><gtr:line2>Rhodes House</gtr:line2><gtr:line3>Building 37-A</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/89567AAF-2DC2-44FC-9DC1-58C569EB26D2"><gtr:id>89567AAF-2DC2-44FC-9DC1-58C569EB26D2</gtr:id><gtr:name>Iron Horse Diagnostics, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BB35394B-CAE4-447B-987C-58186408481A"><gtr:id>BB35394B-CAE4-447B-987C-58186408481A</gtr:id><gtr:name>Stony Brook University</gtr:name><gtr:address><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FA143EC1-E637-4E0C-80ED-0EA8ED214038"><gtr:id>FA143EC1-E637-4E0C-80ED-0EA8ED214038</gtr:id><gtr:name>University of Leuven</gtr:name><gtr:address><gtr:line1>Oude Markt 13</gtr:line1><gtr:line2>Box 5005</gtr:line2><gtr:region>outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B"><gtr:id>22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B</gtr:id><gtr:name>University of Ulm</gtr:name><gtr:address><gtr:line1>Albert Einstein Allee 5</gtr:line1><gtr:line4>Ulm</gtr:line4><gtr:postCode>89081</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB307619-D4FA-427E-A042-09DBEBA84669"><gtr:id>AB307619-D4FA-427E-A042-09DBEBA84669</gtr:id><gtr:name>Swansea University</gtr:name><gtr:address><gtr:line1>Singleton Park</gtr:line1><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BAF7118-A7CB-4385-903E-255DD6F6908A"><gtr:id>7BAF7118-A7CB-4385-903E-255DD6F6908A</gtr:id><gtr:name>Friedrich Schiller University Jena (FSU)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F53AAC5E-F39C-4570-AD7E-0B995E0F8FD2"><gtr:id>F53AAC5E-F39C-4570-AD7E-0B995E0F8FD2</gtr:id><gtr:name>University of Miami</gtr:name><gtr:address><gtr:line1>1204 Dickinson Drive</gtr:line1><gtr:line2>Rhodes House</gtr:line2><gtr:line3>Building 37-A</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CF74FEB1-A15E-4984-A768-008B70F12C51"><gtr:id>CF74FEB1-A15E-4984-A768-008B70F12C51</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Turner</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701923"><gtr:id>499C19F3-4C25-4311-8C10-4ABF5723B905</gtr:id><gtr:title>Biomarkers in motor neuron disease - a longitudinal translational neuroimaging and CSF study</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701923</gtr:grantReference><gtr:abstractText>Motor Neuron Disease (MND) is a devastating neurodegenerative condition affecting around 5000 people in the UK. Loss of motor neurons produces muscle wasting variably affecting the limbs, swallowing, and ultimately breathing. The average survival from symptom onset is 3-4 years. There is no specific test for MND and diagnosis relies mainly on clinical examination. Many patients wait more than a year from symptom onset to receive a firm diagnosis. Over 75 drugs have failed in clinical trials but it can take many months to establish lack of efficacy with certainty. 
This research will study a group of MND patients every six months using magnetic resonance imaging (MRI) of the brain in combination with molecular analysis of the surrounding cerebrospinal fluid (CSF). The Oxford Centre for Functional MRI Brain (FMRIB) has developed techniques highly sensitive to damage within nerve pathways in the brain, and there is local expertise to study the CSF for molecules associated with these changes. In combination it is expected this will provide markers of disease activity to improve the diagnostic process and the way clinical drug trials are monitored, so ineffective drugs can be more quickly discounted. New insights into disease mechanisms may provide novel drug targets.</gtr:abstractText><gtr:technicalSummary>Aims:
To improve the diagnostic algorithm in Motor Neuron Disease (MND), further understanding of pathogenesis (particularly neuro-inflammation), illuminate phenotype heterogeneity, and optimise patient selection and monitoring in therapeutic trials.

Objectives:
The identification of biomarkers through the longitudinal integration of cerebral magnetic resonance structural and functional imaging (MRI), proteomic and cytokine analysis of cerebrospinal fluid (CSF), with clinical study of patients in a multi-disciplinary MND Care Centre.

Design:
Longitudinal and cross-sectional in vivo pathological study.

Methodology:
Seventy-two MND patients, spanning a full range of phenotypes and progression rates, will undergo serial MRI of the brain and CSF analysis. Studies will be performed at baseline and every six months via The Oxford MND Centre where disease progress can be monitored and patient care optimised. Ten asymptomatic subjects, at risk of MND by virtue of homozygous ?D90A? mutations of the superoxide dismutase-1 gene, 10 symptomatic D90A patients and 25 healthy controls will undergo a single MRI and CSF study. MRI studies will be carried out at the Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), involving diffusion tensor, structural and resting state functional MRI (fMRI) sequences at 3 Tesla. Fractional anisotropy (FA) will provide a marker of neuronal integrity in motor and extra-motor regions. Whole-brain unbiased FA analysis will employ FMRIB?s Tract-based Spatial Statistics (TBSS). Locally-developed Probabalistic Tractography (PT) will visualise neuronal pathways and explore connectivity of motor and extra-motor regions. Voxel-based morphometric analysis of structural MRI will detect changes in grey and white matter volume. Resting state fMRI will be studied speculatively as a marker of extra-motor pathology. CSF samples will undergo proteomic analysis using 2D gel electrophoresis and mass spectrometry to identiteins associated with disease progression and phenotype. CSF cytokine analysis will specifically explore neuro-inflammatory processes.

Scientific &amp;amp; Medical Opportunities:
The identification of biomarkers in MND will improve the diagnostic pathway and inform prognosis, permitting ineffective drugs to be more quickly discounted in clinical trials. The study of pre-symptomatic patients has the potential to detect the earliest changes in pathogenesis. The exploration of neuro-inflammatory mechanisms may identify novel targets for drug development. Scientific developments anticipated during the study period include pilot studies in MND patients of ultra-small paramagnetic particles of iron oxide administered intravenously, taken up by macrophages and visualised using MRI to further probe cerebral neuro-inflammatory activity. Developments in spinal cord fMRI at FMRIB will permit changes across the entire central nervous system to be integrated.</gtr:technicalSummary><gtr:fund><gtr:end>2013-08-03</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-08-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1027252</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>Collaboration with artist and MND patient Patrick Joyce and Oxford Museum of Natural History to present exhibit on MND for general public.
Included large head with very long (scaled) motor neuron running around the museum, and pots with human brains to look at.</gtr:description><gtr:id>B0F0E9DC-9254-47C6-B63C-137EFE80E0D6</gtr:id><gtr:impact>Visitor book revealed huge interest from public, including many children</gtr:impact><gtr:outcomeId>5463bdc26a0081.25633517</gtr:outcomeId><gtr:title>Patrick The Optimist</gtr:title><gtr:type>Artistic/Creative Exhibition</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Miami</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>pre-FALS</gtr:description><gtr:id>18006D78-A06A-4B79-BA46-8D0E2D74133D</gtr:id><gtr:impact>Paper on DTI and R-FMRI 2016.
MEG beta band changes paper (HBM) 2016.</gtr:impact><gtr:outcomeId>rJKpPT5WZgF-1</gtr:outcomeId><gtr:partnerContribution>Provision of pre-counselled and pre-tested pre-symptomatic ALS genetic mutation carriers.</gtr:partnerContribution><gtr:piContribution>MEG and MRI study of pre-symptomatic carriers of ALS genetic mutations.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leuven</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Progranulin</gtr:description><gtr:id>923978FF-9E56-42E3-90DA-0F465CBC9FBA</gtr:id><gtr:impact>Not detected in samples</gtr:impact><gtr:outcomeId>a4JSJoJXN6W-1</gtr:outcomeId><gtr:partnerContribution>Assay for progranulin and cystatin C</gtr:partnerContribution><gtr:piContribution>Provision of CSF from ALS patients and healthy controls</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Clinical Research Facilities</gtr:department><gtr:description>Neurofilaments</gtr:description><gtr:id>73A69903-534E-4E5E-BA50-94899A64651C</gtr:id><gtr:impact>Papers on CSF and serum NfL as prognostic marker, and link to DTI metrics 2015.
Multi-centre validation studies (papers 2016).
Planned commercial assay study with IHD.</gtr:impact><gtr:outcomeId>GM4WztyVE23-1</gtr:outcomeId><gtr:partnerContribution>ELISA-based assay for neurofilaments as potential biomarker</gtr:partnerContribution><gtr:piContribution>Provision of longitudinal serum and CSF samples from ALS patients and controls</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Swansea University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Cholesterol metabolomics</gtr:description><gtr:id>DC4F4A3D-B279-4261-8C00-0853582EA367</gtr:id><gtr:impact>Paper published 2016.</gtr:impact><gtr:outcomeId>UfHh5uSo5Ef-1</gtr:outcomeId><gtr:partnerContribution>Cholesterol metabolite analysis as potential biomarkers.</gtr:partnerContribution><gtr:piContribution>Provision of serum and CSF from ALS patients and healthy controls.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Primary Care Health Sciences</gtr:department><gtr:description>Hospital record linkage studies</gtr:description><gtr:id>7FE842A0-EAD8-49A8-A6B6-E22787735A88</gtr:id><gtr:impact>Published studies in ALS relating to cancer 2010, head injury 2010 and cardiovascular fitness 2011, autoimmune disorders 2014, cerebrovascular injury 2015, psychiatric disorders 2016.
Published study in Huntington's relating to cancer 2013.</gtr:impact><gtr:outcomeId>iL5WamLWiPe-1</gtr:outcomeId><gtr:partnerContribution>Access to and statistical interrogation of Oxford and England Hospital Record Databases</gtr:partnerContribution><gtr:piContribution>Knowledge and hypothesis relating to ALS and neurological disease more widely</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MS Metabolomics</gtr:description><gtr:id>A57AD840-97A9-4959-914B-A58BF8C22EFC</gtr:id><gtr:impact>Paper on SPMS metabolomics 2014.</gtr:impact><gtr:outcomeId>ArZyEGgmyEo-1</gtr:outcomeId><gtr:partnerContribution>Mass spectrometry metabolomic analysis</gtr:partnerContribution><gtr:piContribution>Provision of longitudinal CSF samples from ALS patients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>CRUK/MRC Oxford Institute for Radiation Oncology</gtr:department><gtr:description>Neuroinflammation in models of ALS</gtr:description><gtr:id>D758D9EB-D7A4-4494-9DCE-8637D6F8E0E8</gtr:id><gtr:impact>Presentation of data at international meetings.
One major review and 3 original research papers published.</gtr:impact><gtr:outcomeId>C4SB1mgygxj-2</gtr:outcomeId><gtr:partnerContribution>Application of high-field MRI and immune histochemistry of mouse models of ALS providing new insights into role of inflammation in pathogenesis.</gtr:partnerContribution><gtr:piContribution>DPhil student supervision and expertise in ALS.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pharmacology</gtr:department><gtr:description>Neuroinflammation in models of ALS</gtr:description><gtr:id>0FF7A2D2-1C34-47DE-ADDC-A2C1FF6C4684</gtr:id><gtr:impact>Presentation of data at international meetings.
One major review and 3 original research papers published.</gtr:impact><gtr:outcomeId>C4SB1mgygxj-1</gtr:outcomeId><gtr:partnerContribution>Application of high-field MRI and immune histochemistry of mouse models of ALS providing new insights into role of inflammation in pathogenesis.</gtr:partnerContribution><gtr:piContribution>DPhil student supervision and expertise in ALS.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>CRUK/MRC Oxford Institute for Radiation Oncology</gtr:department><gtr:description>Proton spectroscopy metabolomics</gtr:description><gtr:id>8C5B9EC7-23DC-4B10-BC5E-20156B1B3B1A</gtr:id><gtr:impact>Successful grant application to Thierry Latran Foundation 2-year post-doctoral position.
Paper in Neurology based on MS compared to ALS as disease control.
Paper submitted to ALS-FTD on ALS data.</gtr:impact><gtr:outcomeId>MTHStgFc9d9-1</gtr:outcomeId><gtr:partnerContribution>Nuclear magnetic resonance spectroscopy metabolomics expertise.</gtr:partnerContribution><gtr:piContribution>Provision of serial serum and CSF samples from ALS patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Neurosciences</gtr:department><gtr:description>Eye-tracking</gtr:description><gtr:id>6E007CBA-3D12-431A-B8D6-1711724A1229</gtr:id><gtr:impact>Data presented at international and patient-based meetings.
Review of field published in JAMA Neurology 2011. 
Paper in PLoS ONE on novel TMT using eye-tracker 2014.
Paper in ALS-FTD on longitudinal analysis in ALS 2015.</gtr:impact><gtr:outcomeId>ekWZcskTunG-1</gtr:outcomeId><gtr:partnerContribution>Expertise and equipment</gtr:partnerContribution><gtr:piContribution>DPhil student supervision. Expertise in ALS. Patients with ALS.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Friedrich Schiller University Jena (FSU)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>NISALS</gtr:description><gtr:id>F67166E0-B9D1-476D-9077-F560C84167A1</gtr:id><gtr:impact>Consensus statementas on neuroimaging in ALS (Lancet Neurology 2011 and 2015).
Multi-site analysis of T1 and DTI data (paper on DTI 2016).
Paper on clinical correlations 2016</gtr:impact><gtr:outcomeId>QMPgxTnZyAg-1</gtr:outcomeId><gtr:partnerContribution>Online repository for multi-site MRI data for multi-site analyses.</gtr:partnerContribution><gtr:piContribution>Establishment of an international consortium of neuroscientists focused on neuroimaging in ALS.
Organise annual meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Iron Horse Diagnostics, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Neurofilaments</gtr:description><gtr:id>5D4DB0C6-C1C5-4CAB-868F-F586B0E57CE3</gtr:id><gtr:impact>Papers on CSF and serum NfL as prognostic marker, and link to DTI metrics 2015.
Multi-centre validation studies (papers 2016).
Planned commercial assay study with IHD.</gtr:impact><gtr:outcomeId>GM4WztyVE23-2</gtr:outcomeId><gtr:partnerContribution>ELISA-based assay for neurofilaments as potential biomarker</gtr:partnerContribution><gtr:piContribution>Provision of longitudinal serum and CSF samples from ALS patients and controls</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ulm</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Neurofilaments</gtr:description><gtr:id>412A9854-07B7-47F6-829A-CA2E9F45E5FB</gtr:id><gtr:impact>Papers on CSF and serum NfL as prognostic marker, and link to DTI metrics 2015.
Multi-centre validation studies (papers 2016).
Planned commercial assay study with IHD.</gtr:impact><gtr:outcomeId>GM4WztyVE23-3</gtr:outcomeId><gtr:partnerContribution>ELISA-based assay for neurofilaments as potential biomarker</gtr:partnerContribution><gtr:piContribution>Provision of longitudinal serum and CSF samples from ALS patients and controls</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stony Brook University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Stony Brook University</gtr:description><gtr:id>BA8494A2-0679-4089-B5FC-8B78C14349B9</gtr:id><gtr:impact>Paper in PLoS ONE on biomarker potential</gtr:impact><gtr:outcomeId>jcC7VjEoMT7-1</gtr:outcomeId><gtr:partnerContribution>Machine-learning analysis as potential biomarker.</gtr:partnerContribution><gtr:piContribution>Provision of R-fMRI data in ALS.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>NEALS annual meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A0FC7F90-228D-426C-93B8-37314D84D061</gtr:id><gtr:impact>North-east ALS Consortium, USA annual meeting for ~150 PIs and team members. Invited presentation on neuroimaging.

New collaborations and increased international reputation.</gtr:impact><gtr:outcomeId>TeYoD1kvNWX</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ALSA Drug Discovery in ALS, Washington</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>89C7A326-8241-4EF5-B1AB-F25B6B45D68A</gtr:id><gtr:impact>~100 scientists, clinicians, Pharma representatives reviewing prospects for new drugs in ALS. Invited speaker on neuroimaging biomarkers.

Future collaboration potential and increased international reputation in the field.</gtr:impact><gtr:outcomeId>MNQjdqRLDHG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Biomedical Research Advisory Panel</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8993067B-F1DD-4B13-92C0-C9813A7FB7DF</gtr:id><gtr:impact>Discussion and scoring of grant applications

Helping to shape national MND research</gtr:impact><gtr:outcomeId>rer6mLPGY1v</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.mndassociation.org</gtr:url><gtr:year>2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge Neuroscience meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>16EBF386-15F3-407B-B414-6C20F3F8FDBD</gtr:id><gtr:impact>Invited presentation on 'New frontiers in ALS'.

Education of other neuroscience centres and raised profile as ALS research leader.</gtr:impact><gtr:outcomeId>QFTH7cHsu54</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cherwell School Science Enrichment Programme</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D4147A8C-7E71-4430-9854-3E65222A2C75</gtr:id><gtr:impact>Annual presentation to 50-100 local sixth formers on my research and medical careers in general.

Several students keen to find out more. Asked by school to repeat on an annual basis.</gtr:impact><gtr:outcomeId>rQ2uchNKvkv</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Awareness Campaign</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>163AC171-897F-42E5-96B5-23F076FB7742</gtr:id><gtr:impact>Informal briefing of parliamentarians on MND issues.

Raised awareness of MND needs, and my role as opinion leader.</gtr:impact><gtr:outcomeId>Mc8MBsAwr9s</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Care Centre Meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BA28736E-355E-4111-A0C3-F299D350EC0D</gtr:id><gtr:impact>Annual meeting of care centre directors, co-directors and coordinators to review best practice and future intiatives.</gtr:impact><gtr:outcomeId>56d2e957e37498.05777157</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Thumbprint</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F2E3BF34-164C-40BD-A805-630589893653</gtr:id><gtr:impact>Articles highlighting my BioMOx biomarker study in national magazine for MND patients.
Autumn 2012 - letter in reply to PLS patient asking about research issues.

Significant boost to recruitment of participants.
Raising awareness of the value of clinical research.</gtr:impact><gtr:outcomeId>C9959F5C500</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>King's MSc Neuroscience</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>36DDE02E-29AB-4D7D-A9FC-CF077A0986E1</gtr:id><gtr:impact>Reviewed marking scheme and course material.

Educational value in understanding how MSc courses run in other institutions</gtr:impact><gtr:outcomeId>fagP1kGGvJs</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Association of Sri Lankan Neurologists' Scientific Sessions</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>357F171D-6546-4BBC-8D2E-23CEF238E3BA</gtr:id><gtr:impact>~100 neurologists and medical trainees. Invited presentation on 'Advances in Diagnosis and Management in MND'.

Foster specialist trainee links with UK.</gtr:impact><gtr:outcomeId>KQvnzAcVVRy</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ALSA Biomarker Initiative Boston</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B9889CC8-3765-4476-9E48-D990E5D4EE82</gtr:id><gtr:impact>~20 ALS bioamrker experts. Invited presentation on neuroimaging.

New collaboration potential.</gtr:impact><gtr:outcomeId>FfPqMxrVFbe</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ABN Clinical Research Advisory Committee</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6533A52D-3FE6-4110-A007-B99DA7AA66B7</gtr:id><gtr:impact>Discussion of ABN strategy and funding for clinical research in neurology.

Raised personal profile and chance to shape future research agenda.</gtr:impact><gtr:outcomeId>it46JHKZCmL</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>www.patricktheoptimist.org</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EE59AE4A-D9F4-49EE-9FB8-27CF5F3C18C6</gtr:id><gtr:impact>No. 2 of MND patient's national campaign to paint 100 'Incurable Optimists' before he dies of MND. My image, among others, featured all over the London Underground for one month.

Large number of website hits.</gtr:impact><gtr:outcomeId>neAHB8rA4j1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cytokinetics Tirasemtiv trial</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>71D85F5E-D32E-4CAF-BD5C-5B2E11FBD046</gtr:id><gtr:impact>Enrollment of participants in Phase IIb study.

Enhancement of Oxford's status as clinical trials centre in ALS.
Increased recruitment to clinical research more widely.</gtr:impact><gtr:outcomeId>HDXirV31Rid</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ALSA Patient Group meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>89F7AF6B-A637-4687-8F5B-9FCDE670DFB4</gtr:id><gtr:impact>Invited talk on ALS biomarker research.

Facilitated fund-raising for ALSA and raised personal profile as international research and opinion leader.</gtr:impact><gtr:outcomeId>Ascp3uaTDxQ</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA regional patient meetings</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>26CEDA62-E4F4-4259-939E-329F41DD7336</gtr:id><gtr:impact>Annual regional branch meetings to 25-50 patient and carer attendees. Presented biomarker research progress.

2011 Oxfordshire branch
2011 National Spring Conference (Cambridge)
2012 Cambridgeshire branch
2013 Oxford, Gloucester &amp;amp; Reading West branches
2013 Reading
2015 Oxfordshire

Improved awareness and hope for patients and carers.
Offers to participate in research.</gtr:impact><gtr:outcomeId>eKb58QHBRa3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2011,2012,2013,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HRH The Princess Royal at The Royal Society</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8681A370-760D-4BDE-953E-7AC40756E89A</gtr:id><gtr:impact>Discussion with HRH and donors on the challenges of ALS care and research

Raising awareness of ALS and MNDA funding to support research</gtr:impact><gtr:outcomeId>ZNo3RF5iTym</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Fort Denison Summit, Sydney</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>53ADFF2D-D534-471A-AF1E-6A25E53C6938</gtr:id><gtr:impact>20 key opinion leaders in ALS whom I convened for a workshop 'Challenging Dogma' to debate current ideas about pathogenesis.

Review article. Increased international reputation as ALS expert.</gtr:impact><gtr:outcomeId>YFcpG5NZ4Qf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hannover Neurosciences meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>04903402-0770-4EB4-AA6C-914B1C39861B</gtr:id><gtr:impact>Invited talk on ALS biomarker research.

Raised international profile as research leader in field.</gtr:impact><gtr:outcomeId>ZA7TFsRwzHC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Therapists MND Workshop</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>660E8C17-9737-4C85-A3D3-938E7C68D960</gtr:id><gtr:impact>Annual workshop to ~50 healthcare therapists and 25 Palliative Care Physicians involved in the care of MND patients around the UK. Topics:

Diagnosis and management in ALS
Biomarker research in ALS
Respiratory and secretion management in ALS
Palliative care in ALS

Greater awareness and improved management.</gtr:impact><gtr:outcomeId>JUqMrvph12q</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2010,2011,2012,2013,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Board of Trustees</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>23143A6D-D9E1-4D4D-A244-6BDA01EAE725</gtr:id><gtr:impact>Overview of MND and the BioMOx project.

Raised awareness among Trustees and Donors of the challenge and insecurity of the Clinical Academic career pathway.</gtr:impact><gtr:outcomeId>7E937730289</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wellcome Trust/MRC panel on incidental findings in research</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EBD1ABF2-E594-4883-B896-E2AAF2F9F99A</gtr:id><gtr:impact>Review of guidelines for IFs.

Contributed to shaping emerging national consensus in area of research IFs.</gtr:impact><gtr:outcomeId>cQ9LhcPPJQZ</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ontario Brain Institute</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>05FFFFC6-58E1-4681-94DE-06C54C1FE6C2</gtr:id><gtr:impact>Invited to review 5-year programme and make recommendations for improvement.

Increased awareness of other international studies and personal profile-raising as opinion leader in field.</gtr:impact><gtr:outcomeId>DC7Xxu1G9GD</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ondri.ca</gtr:url><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RSCI inuagural neuroscience symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>22DB0950-D9FE-4893-8F9A-577316D6CA47</gtr:id><gtr:impact>~100 scientists. Invited keynote talk on 'Biomarkers in ALS'

Increased international awareness and reputation in the field.</gtr:impact><gtr:outcomeId>QLWiJCsdMrn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Palliative Care Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6E6588B2-BB80-4627-A327-20372B626F0C</gtr:id><gtr:impact>Invited lecture on 'Palliative Care issues in MND' to 150 Palliative Care professionals.

Interest and awareness of MND-related issues.</gtr:impact><gtr:outcomeId>bMQdWhHq3iR</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>www.oxfordmnd.net</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3A03CDF9-CD57-4609-AAB1-CCCFC46DA249</gtr:id><gtr:impact>Development and maintenance of website for Oxford MND Centre.

Increased awareness of Centre's activity, information for patients about Care &amp;amp; Research.</gtr:impact><gtr:outcomeId>E2EE66F82C7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.oxfordmnd.net</gtr:url><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA Major donor presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>41DA1F14-12BB-42FE-B8ED-28A37AAA3B69</gtr:id><gtr:impact>Annual MND Association-organised Royal Society presentation of my ALS research to major donors.
Visits to Oxford MND Care &amp;amp; Research Centre - tour of labs 2012, 2013.
Lady Edith Wolfson Day at Sheffield 2013.

Interest in continued funding of ALS research.</gtr:impact><gtr:outcomeId>owf7zHv2qpR</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio Oxford MND Awareness Week</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7F36A465-F473-492B-8AE9-973E542B25DC</gtr:id><gtr:impact>Discussion of MND Care and Research on BBC Radio Oxford morning show as part of MND Awareness Week

Several supportive callers to studio after interview.</gtr:impact><gtr:outcomeId>kjnjN3wmULk</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BANN meeting Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>27FC145B-FDC2-44A9-B43E-1D785A2BAD9C</gtr:id><gtr:impact>British Association of Neurological Nurses Annual Conference invited speaker on 'The Challenges of MND Research'.

Improved awareness and care of MND patients.</gtr:impact><gtr:outcomeId>rkMKtMvBoUq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cold Spring Harbor Banbury Workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1C7E2FF1-872C-4D41-9B98-9A3F5B4E4284</gtr:id><gtr:impact>I convened a meeting of internationally-leading neurobiologists, and ALS clinicians to discuss 'Evolutionary &amp;amp; Developmental considerations in the pathogenesis of ALS/FTD'.
Hosted by the Banbury Workshop group at Cold Spring Harbor in conjunction with the ALS Association USA.

Unique meeting, with highly stimulating two days' discussion and opportunity for new collaborations.
Raised personal profile as leader in ALS research strategy.</gtr:impact><gtr:outcomeId>g89HRFcJrZK</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International ALS Conference Tarrytown</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>80B4371E-C32E-4495-9FBA-60A4974E6047</gtr:id><gtr:impact>~100 international ALS experts reviewing current theories of pathogenesis.

Edited review for Annals of Neurology. Increased international impact.</gtr:impact><gtr:outcomeId>nzHF8qL2zsB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Departmental MRC PhD Studentship Matt Evans</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4ECDB3D4-3ADE-472E-828B-52F3848E1DC4</gtr:id><gtr:outcomeId>0EEE5DC54F50</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100100</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Thierry Latran Foundation 4th Project Call</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Thierry Latran Foundation</gtr:fundingOrg><gtr:fundingRef>PROMISES</gtr:fundingRef><gtr:id>9AD37486-9BE3-48F6-ACFF-3A5DC04E5078</gtr:id><gtr:outcomeId>JHEPLs1LFHz</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MNDA small grants</gtr:description><gtr:end>2010-10-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:fundingRef>1st NiSALS meeting</gtr:fundingRef><gtr:id>4E38BEAA-BB11-4284-AB27-B596094FEF69</gtr:id><gtr:outcomeId>54639ad68da624.02277523</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Oxford Health Services Research Committee Project Grant</gtr:description><gtr:end>2012-02-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>A4CD9AEB-2509-4FF4-85B2-5A0A69DB8218</gtr:id><gtr:outcomeId>9EE5631756D0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rhodes Foundation DPhil Scholarship Rakesh Sharma</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>Rhodes Trust</gtr:fundingOrg><gtr:id>E21FFDF9-C6EA-47E8-932C-C6C6CA41921A</gtr:id><gtr:outcomeId>B81365323C40</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ENMC Workshop on EU Consensus in Amyotrophic lateral sclerosis (ALS)</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>5D9E82A1-9D48-4AA7-95A4-7F9AC08DF5B2</gtr:id><gtr:impact>Led to formation of ENCALS - The European Network for the Cure of ALS which has led on to numerous research grants, meetings, and clinical trials.</gtr:impact><gtr:outcomeId>PiBbdP4VUhq</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type><gtr:url>http://www.encals.eu</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>The Neuroimaging Symposium in Amyotrophic lateral sclerosis (ALS) (NISALS)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>10AE95B2-3A4E-4A86-B27C-2E801BFD9F89</gtr:id><gtr:impact>I convened the first meeting in 2010, now annual, of global researchers studying ALS using neuroimaging. Guidelines were developed and published in Lancet Neurology PMID:21511189. Second meeting in Jena Germany 2011 has laid foundation for standardization and harmonization of MRI data across centres. Meeting in Miami developing multi-centre collaborative MRI study. Meetings in Milan, Leuven, Orlando and Dublin have developed multi-centre projects and Governance framework.</gtr:impact><gtr:outcomeId>PTWjRE1fi33</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://europepmc.org/abstract/MED/21511189</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Roadmap for 'wet' biomarker development in Amyotrophic lateral sclerosis (ALS)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>575507EC-CC3D-4217-8C42-7232BD4D015E</gtr:id><gtr:impact>Produced international consensus statement (with me as co-first author) on future development and validation of 'wet' biomarkers in ALS, Published in ALS journal.</gtr:impact><gtr:outcomeId>BZNfVNDn92W</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MND Association UK National Strategy Manifesto</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1DE6DEAE-DDF2-4F1D-93A7-13D18E5CEC3A</gtr:id><gtr:outcomeId>dJJTHaANu72</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Wellcome Trust/MRC panel on incidental findings in research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>49FA7C11-BD09-4F96-B6C6-8B8CE1D8297B</gtr:id><gtr:impact>Development of consensus guidelines on management of incidental findings during the course of research participation.</gtr:impact><gtr:outcomeId>hKYdKn3FFwU</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Ethical approval to seek consent for extra sample of CSF and blood from patients having routine investigations, to use as disease controls in biomarker studies.</gtr:description><gtr:id>C2F27B8B-2F18-49DE-8061-CB53BB0B4458</gtr:id><gtr:impact>Access to disease controls for ALS biomarker development, including contribution to standardisation efforts.
New collaborations with local groups increases sample collecting infrastructure.</gtr:impact><gtr:outcomeId>5463b7ae9492b4.66224218</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Oxford Biomarker Bank</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Longitudinal MRI, CSF and blood from large group of ALS patients</gtr:description><gtr:id>6AA67C4A-1244-437F-90D1-5B8967DEAFB8</gtr:id><gtr:impact>Candidate MRI and biofluid biomarkers.
Major finding of NfL as a prognostic biomarker through sample sharing with QMUL</gtr:impact><gtr:outcomeId>AC2wsjcu16C</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ALS biomarkers</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E38D107B-F02B-41D6-AFFF-711C36ADF7DC</gtr:id><gtr:title>Unmasking of incipient amyotrophic lateral sclerosis by botulinum toxin therapy.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4764aa823b7a020b3590bce2cc799303"><gtr:id>4764aa823b7a020b3590bce2cc799303</gtr:id><gtr:otherNames>Kent L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>pm_12643_23_23400499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28F3F632-D8EC-480E-9313-63BC523DF117</gtr:id><gtr:title>Identification of distinct circulating exosomes in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Annals of clinical and translational neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6de5ee73dccccec3d9bb9e85c3b55fc4"><gtr:id>6de5ee73dccccec3d9bb9e85c3b55fc4</gtr:id><gtr:otherNames>Tomlinson PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2328-9503</gtr:issn><gtr:outcomeId>56d2c61ca075b2.56649411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCE6FFD8-3694-4930-9419-36773BC22D94</gtr:id><gtr:title>Concordance between site of onset and limb dominance in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>54637a534104b8.68483223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78EAA216-B913-4B40-A9EB-9EDDD10170E6</gtr:id><gtr:title>Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].</gtr:title><gtr:parentPublicationTitle>BMC neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7bc8538c82db76d6e2482ddeeb2d3d0"><gtr:id>d7bc8538c82db76d6e2482ddeeb2d3d0</gtr:id><gtr:otherNames>Al-Chalabi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-2377</gtr:issn><gtr:outcomeId>pm_12643_23_21936930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5D7583F-FA09-4139-8D58-FDE30F3E4DF9</gtr:id><gtr:title>Diffusion imaging of whole, post-mortem human brains on a clinical MRI scanner.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04d30a2d2fe723a57ef1a3e10ef6d8ac"><gtr:id>04d30a2d2fe723a57ef1a3e10ef6d8ac</gtr:id><gtr:otherNames>Miller KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>56d2c61fb28971.28059657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>435E442D-6FB2-4162-B640-EC8349E8A958</gtr:id><gtr:title>Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be639fc9a93f43af13da298a28a31cd"><gtr:id>3be639fc9a93f43af13da298a28a31cd</gtr:id><gtr:otherNames>Fois AF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>0BAB79E7E49</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EDA1F76-C559-4901-AAD0-ACABC385C729</gtr:id><gtr:title>Cardiovascular fitness as a risk factor for amyotrophic lateral sclerosis: indirect evidence from record linkage study.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12643_23_22072701</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91781E5F-F3F4-4104-AA85-825F54F7466E</gtr:id><gtr:title>CSF neurofilament light chain reflects corticospinal tract degeneration in ALS.</gtr:title><gtr:parentPublicationTitle>Annals of clinical and translational neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5248c85a0deded9bb978e3443bdfc858"><gtr:id>5248c85a0deded9bb978e3443bdfc858</gtr:id><gtr:otherNames>Menke RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2328-9503</gtr:issn><gtr:outcomeId>56d2c61c0b9335.87393765</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89E09038-4646-4992-843C-D6A65AB54383</gtr:id><gtr:title>Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c0ee7b319752e06e1099570139e53bb"><gtr:id>4c0ee7b319752e06e1099570139e53bb</gtr:id><gtr:otherNames>B?umer D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>54637a539f9228.00996553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6BF0884-339C-4BA6-B8DE-56C177AE106E</gtr:id><gtr:title>Controversies and priorities in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_12643_23_23415570</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FBF35CF-88E0-480A-AEF0-7F23C31E7736</gtr:id><gtr:title>Diffusion tensor imaging in sporadic and familial (D90A SOD1) forms of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Archives of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ca3ebca71c2613dc6c623c79c86deae"><gtr:id>0ca3ebca71c2613dc6c623c79c86deae</gtr:id><gtr:otherNames>Stanton BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0003-9942</gtr:issn><gtr:outcomeId>04E7B77BB39</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD40E030-7391-407A-8C4D-CBB39F2818B9</gtr:id><gtr:title>Differential corticospinal tract degeneration in homozygous 'D90A' SOD-1 ALS and sporadic ALS.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55ae7b7bcfff6420c894ef7af7b68e4a"><gtr:id>55ae7b7bcfff6420c894ef7af7b68e4a</gtr:id><gtr:otherNames>Blain CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56d2c61f5c02e4.20278086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F64D2B4-5607-44DC-9F9F-86DB99E86344</gtr:id><gtr:title>EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2deb3bad43536c8c939526c0265dbb29"><gtr:id>2deb3bad43536c8c939526c0265dbb29</gtr:id><gtr:otherNames>Filippi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>56d2c6205a98b8.00614899</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>360CF4C6-B8B0-4F9A-BA83-AC77C919DC7E</gtr:id><gtr:title>Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4cf367b6fa6cc2170f00d197d4c924b"><gtr:id>b4cf367b6fa6cc2170f00d197d4c924b</gtr:id><gtr:otherNames>Bowser R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>54637a5550a428.76487147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA3D1909-AED1-4DAE-BE8B-CB6A0C7A9DAF</gtr:id><gtr:title>Amyotrophic Lateral Sclerosis and the Frontotemporal Dementias</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4cf367b6fa6cc2170f00d197d4c924b"><gtr:id>b4cf367b6fa6cc2170f00d197d4c924b</gtr:id><gtr:otherNames>Bowser R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>9780199590674</gtr:isbn><gtr:outcomeId>UV1p5tSE8Bp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AA13E1F-0C76-4FB5-A416-1189B9A92703</gtr:id><gtr:title>Eye-tracking in amyotrophic lateral sclerosis: A longitudinal study of saccadic and cognitive tasks.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d03ffb9b885afe6a58631746bc84369"><gtr:id>1d03ffb9b885afe6a58631746bc84369</gtr:id><gtr:otherNames>Proudfoot M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>56d2c61cd0b7b4.77451711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1166E72-89CA-403D-80E5-1D566389609C</gtr:id><gtr:title>Are neurofilaments heading for the ALS clinic?</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56d2c61a66a911.69968598</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DE6C0C4-25A1-4805-9BAA-18BBF2C78F20</gtr:id><gtr:title>Geographical clustering of amyotrophic lateral sclerosis in South-East England: a population study.</gtr:title><gtr:parentPublicationTitle>Neuroepidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02a3b0ae44952c327deb72e47fcabf9f"><gtr:id>02a3b0ae44952c327deb72e47fcabf9f</gtr:id><gtr:otherNames>Scott KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0251-5350</gtr:issn><gtr:outcomeId>E98CBEE774F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E716CAF-4B01-4883-B59D-28DE72BFDA93</gtr:id><gtr:title>Towards a neuroimaging biomarker for amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>54637a54532698.32997509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A42EC0B5-F28A-4FD6-ADA2-B7D814C0BF25</gtr:id><gtr:title>An eye-tracking version of the trail-making test.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebd4f8ec0d8b4f458086eedf1b434953"><gtr:id>ebd4f8ec0d8b4f458086eedf1b434953</gtr:id><gtr:otherNames>Hicks SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54637a566cb172.32338605</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53AB12C1-49EC-415E-A399-5E5172B33F7C</gtr:id><gtr:title>Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_12643_23_23946298</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D6FDC99-D11D-400C-819D-801F23326D09</gtr:id><gtr:title>A proposed staging system for amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6afdab96df90f6df25fd1128f353de57"><gtr:id>6afdab96df90f6df25fd1128f353de57</gtr:id><gtr:otherNames>Roche JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_12643_23_22271664</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13DA96FC-0CED-4536-8FA8-774A98A35A8E</gtr:id><gtr:title>Inflammation and neurovascular changes in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e7a2aaff095ddfd459f6f62ef8b765c"><gtr:id>3e7a2aaff095ddfd459f6f62ef8b765c</gtr:id><gtr:otherNames>Evans MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>pm_12643_23_23110760</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59E15EEC-4022-4C7C-8A0E-AF82D2E79DBC</gtr:id><gtr:title>Biomarkers in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>56d2c6214cdd52.43755274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8248FE09-C0B5-4BB5-A986-CC1FA667B66B</gtr:id><gtr:title>MRI as a frontrunner in the search for amyotrophic lateral sclerosis biomarkers?</gtr:title><gtr:parentPublicationTitle>Biomarkers in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1752-0363</gtr:issn><gtr:outcomeId>pm_12643_23_21319968</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9D454B6-6071-4E9E-B156-83E679A6C63F</gtr:id><gtr:title>The association between ALS and population density: A population based study.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02a3b0ae44952c327deb72e47fcabf9f"><gtr:id>02a3b0ae44952c327deb72e47fcabf9f</gtr:id><gtr:otherNames>Scott KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-180X</gtr:issn><gtr:outcomeId>54637a52c06bd1.46265672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BDA8AC3-F844-4BCE-80F0-880EE16934D8</gtr:id><gtr:title>Pattern of spread and prognosis in lower limb-onset ALS.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-180X</gtr:issn><gtr:outcomeId>54637a526bcb44.01836113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56E4A153-BE1B-4205-85B7-1B0DCD5FDDA7</gtr:id><gtr:title>Advances in the application of MRI to amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Expert opinion on medical diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1753-0059</gtr:issn><gtr:outcomeId>54637a549d0c31.32788068</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92899CF4-6FCC-46BC-A315-AC8CEB9955A8</gtr:id><gtr:title>Reduced cancer incidence in Huntington's disease: record linkage study clue to an evolutionary trade-off?</gtr:title><gtr:parentPublicationTitle>Clinical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9163</gtr:issn><gtr:outcomeId>pm_12643_23_23017147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F87B601-E471-412C-B123-20FCE7E041BB</gtr:id><gtr:title>Promoting clinical and patient-oriented research to identify the pathogenesis of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a6684e12293eedd4c487bdc6661723f"><gtr:id>7a6684e12293eedd4c487bdc6661723f</gtr:id><gtr:otherNames>Mitsumoto H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12643_23_23678875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C8B594A-E8B6-4CED-8134-A5161863613E</gtr:id><gtr:title>Defective cholesterol metabolism in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of lipid research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/431a767937725fdd7cabdb422318cce0"><gtr:id>431a767937725fdd7cabdb422318cce0</gtr:id><gtr:otherNames>Abdel-Khalik J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2275</gtr:issn><gtr:outcomeId>58bc2d23252698.77004357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5929185F-0E75-497D-8407-0320866F128C</gtr:id><gtr:title>Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9ff70460a8a25a64715383958cc1a82"><gtr:id>a9ff70460a8a25a64715383958cc1a82</gtr:id><gtr:otherNames>Majounie E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_12643_23_22406228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CBD5828-458F-4E08-AB47-F6EBADDA14E6</gtr:id><gtr:title>T2-weighted MRI detects presymptomatic pathology in the SOD1 mouse model of ALS.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e7a2aaff095ddfd459f6f62ef8b765c"><gtr:id>3e7a2aaff095ddfd459f6f62ef8b765c</gtr:id><gtr:otherNames>Evans MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>pm_540e15be15b77563d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>938DCB7C-5997-4FC1-92F0-C85E2E24CE06</gtr:id><gtr:title>Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5248c85a0deded9bb978e3443bdfc858"><gtr:id>5248c85a0deded9bb978e3443bdfc858</gtr:id><gtr:otherNames>Menke RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>54637a5768bb70.81114586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4664DFB7-7423-473E-B740-F141536CD41D</gtr:id><gtr:title>Does variation in neurodegenerative disease susceptibility and phenotype reflect cerebral differences at the network level?</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d804af8bcf32af37ab3754538291612"><gtr:id>3d804af8bcf32af37ab3754538291612</gtr:id><gtr:otherNames>Eisen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12643_23_23879681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F3F7547-25C0-4017-A126-7C575F96097D</gtr:id><gtr:title>Increased premorbid physical activity and amyotrophic lateral sclerosis: born to run rather than run to death, or a seductive myth?</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12643_23_23447649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3421C683-22D6-4C52-BB1A-791D908B86C5</gtr:id><gtr:title>The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>54637a52e7a893.18560134</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9701CFF8-2328-4BD9-A5AE-51A6DE8120A0</gtr:id><gtr:title>Progressive hemiparesis (Mills syndrome) with aphasia in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c0ee7b319752e06e1099570139e53bb"><gtr:id>4c0ee7b319752e06e1099570139e53bb</gtr:id><gtr:otherNames>B?umer D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>54637a564551b8.57087489</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E6D7ABB-38E4-464B-BF02-FF730AF97E23</gtr:id><gtr:title>Catastrophic hyperkalaemia following administration of suxamethonium chloride to a patient with undiagnosed amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>54637a55251a30.71455313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57ADA564-C517-41F9-B7A2-3E79C8D1677A</gtr:id><gtr:title>Some difficult decisions in ALS/MND.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3c5c8cdfce609406348be5245a40216"><gtr:id>a3c5c8cdfce609406348be5245a40216</gtr:id><gtr:otherNames>Oliver DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-180X</gtr:issn><gtr:outcomeId>54637a531d69d2.07939371</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B09A1C8D-E4D0-4542-BBA8-40FCC6D6D582</gtr:id><gtr:title>Public awareness of motor neuron disease.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/273874cf38403a83a40973a1f0734a7f"><gtr:id>273874cf38403a83a40973a1f0734a7f</gtr:id><gtr:otherNames>Davies Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-180X</gtr:issn><gtr:outcomeId>56d2c61fee7e76.69864096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F4CD33F-A96A-44D5-B0BE-6C7CDB5B76F8</gtr:id><gtr:title>CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e7a2aaff095ddfd459f6f62ef8b765c"><gtr:id>3e7a2aaff095ddfd459f6f62ef8b765c</gtr:id><gtr:otherNames>Evans MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2051-5960</gtr:issn><gtr:outcomeId>pm_540e15be15b8105ff</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37D4ED7A-8FE9-4289-A6F7-6EAB859E56A0</gtr:id><gtr:title>Mimics and chameleons in motor neurone disease.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>pm_12643_23_23616620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60D0896C-05DE-463E-BD2F-81585428B5C1</gtr:id><gtr:title>Oculomotor dysfunction in amyotrophic lateral sclerosis: a comprehensive review.</gtr:title><gtr:parentPublicationTitle>Archives of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f01aee55e92ee99444433dc058e18197"><gtr:id>f01aee55e92ee99444433dc058e18197</gtr:id><gtr:otherNames>Sharma R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-9942</gtr:issn><gtr:outcomeId>54637a54ef8e48.52733640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30FA80B2-F296-4FF9-A1CA-FF6AB1B51EF8</gtr:id><gtr:title>Motor neurone disease is a clinical diagnosis.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>pm_12643_23_23144309</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F0B57EA-A180-478C-A0A1-57953C107A5B</gtr:id><gtr:title>Lockhart Clarke's contribution to the description of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>54637a536c3db3.17901832</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46B35778-357A-4291-B5C3-05F4DB38D0BD</gtr:id><gtr:title>Peer recommendations on how to improve clinical research, and Conference wrap-up.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acd61e2545d67af6c3c96e8742a84f6b"><gtr:id>acd61e2545d67af6c3c96e8742a84f6b</gtr:id><gtr:otherNames>Chad DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12643_23_23678882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D6C1F66-0117-416B-A3A8-01B50C0F579E</gtr:id><gtr:title>Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c12335f657ccdc4978bff1308a85190e"><gtr:id>c12335f657ccdc4978bff1308a85190e</gtr:id><gtr:otherNames>Filippini N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>54637a53ef0dc6.80165133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CED99231-3D64-4C79-AF65-DF7D55F27CDC</gtr:id><gtr:title>Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cda758646dc6e6fea4163230f74012c1"><gtr:id>cda758646dc6e6fea4163230f74012c1</gtr:id><gtr:otherNames>UKMND-LiCALS Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_12643_23_23453347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4B38135-841B-4E0D-A2ED-03C99808353C</gtr:id><gtr:title>Multiple kernel learning captures a systems-level functional connectivity biomarker signature in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac23f0115c5aab1cd4bb547272d0a65e"><gtr:id>ac23f0115c5aab1cd4bb547272d0a65e</gtr:id><gtr:otherNames>Fekete T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54637a569be7d9.38186887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DBBE847-D050-4BD4-96CC-99173186354D</gtr:id><gtr:title>Teaching NeuroImages: somatic muscle fasciculations detected by electrocardiography.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_12643_23_22249505</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABEF5838-E16B-46A3-9BDD-6F16280AC3A3</gtr:id><gtr:title>The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6e261b5ce65b87737e7eb4b642351e4"><gtr:id>d6e261b5ce65b87737e7eb4b642351e4</gtr:id><gtr:otherNames>Gray E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>56d2c61d099133.64631758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7532550-9942-4877-B49B-2D80CE24D6EF</gtr:id><gtr:title>Magnetic resonance imaging of pathological processes in rodent models of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e7a2aaff095ddfd459f6f62ef8b765c"><gtr:id>3e7a2aaff095ddfd459f6f62ef8b765c</gtr:id><gtr:otherNames>Evans MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-180X</gtr:issn><gtr:outcomeId>pm_12643_23_22117132</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94C5ADB6-8CF7-4DC9-9A7E-9C043ADF0DA3</gtr:id><gtr:title>Low index-to-ring finger length ratio in sporadic ALS supports prenatally defined motor neuronal vulnerability.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc1ff082016dd34c0b053ded4582c910"><gtr:id>bc1ff082016dd34c0b053ded4582c910</gtr:id><gtr:otherNames>Vivekananda U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>54637a54cb46f2.14550311</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97030F64-49FA-4448-83A6-02306873DE21</gtr:id><gtr:title>The internet for self-diagnosis and prognostication in ALS.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbfbba64e0bed5a5bd0e165199be7334"><gtr:id>bbfbba64e0bed5a5bd0e165199be7334</gtr:id><gtr:otherNames>Chen Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-180X</gtr:issn><gtr:outcomeId>54637a53c72284.98777621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B69DF622-2676-4F57-8719-795283CAB327</gtr:id><gtr:title>Understanding Medical Research: The Studies That Shaped Medicine</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5741ac36901cd321b91d3304f84027a"><gtr:id>b5741ac36901cd321b91d3304f84027a</gtr:id><gtr:otherNames>Martin R. Turner, Kevin Talbot</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>cVCvoG3rKQe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0F4EF1E-2FCA-4AB2-BB35-679B39F546C4</gtr:id><gtr:title>Nerve fibre degeneration in the brain in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_12643_23_22399796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03A73443-9784-4A9A-88AC-A0CA0404E2BB</gtr:id><gtr:title>Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Archives of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5248c85a0deded9bb978e3443bdfc858"><gtr:id>5248c85a0deded9bb978e3443bdfc858</gtr:id><gtr:otherNames>Menke RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-9942</gtr:issn><gtr:outcomeId>pm_12643_23_22910997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A160E3F4-81E6-4910-AC7C-D7E2FC0A4D2B</gtr:id><gtr:title>An elusive cause for a progressive neuropathy.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41fbbad9f0a6954389ba269e1ef9be19"><gtr:id>41fbbad9f0a6954389ba269e1ef9be19</gtr:id><gtr:otherNames>Aurangzeb S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>56d2c61e0c2952.48443595</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65E6B2B9-043D-40A7-B9F1-EDB03FE89660</gtr:id><gtr:title>Reduction of elevated IGF-1 levels in coincident amyotrophic lateral sclerosis and acromegaly.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d352246b0fe8e57cdd6e2c0aebfefa31"><gtr:id>d352246b0fe8e57cdd6e2c0aebfefa31</gtr:id><gtr:otherNames>Pereira EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-180X</gtr:issn><gtr:outcomeId>54637a5219eac2.97100211</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2C2E58D-6218-45A8-8015-3F92EE81C2A2</gtr:id><gtr:title>Young-onset amyotrophic lateral sclerosis: historical and other observations.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_12643_23_22661746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DFB94BB-7E33-4FC8-9AAC-D3FDF6D27D62</gtr:id><gtr:title>Trends in death certification for multiple sclerosis, motor neuron disease, Parkinson's disease and epilepsy in English populations 1979-2006.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/984b2948f6ccfddfc8d72c9a1f7599c6"><gtr:id>984b2948f6ccfddfc8d72c9a1f7599c6</gtr:id><gtr:otherNames>Goldacre MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>56d2c6202bb703.37749386</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A8A308E-60F5-4E3C-BEBF-3645ADF5DD8F</gtr:id><gtr:title>Oxford Diagnosis &amp;amp; Treatment in Internal Medicine</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>546395bbe50a04.15246122</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82BAAA16-D75E-4768-876C-9D280ACB9779</gtr:id><gtr:title>Faulty brakes: An inhibitory neuronal deficit in the pathogenesis of motor neuron disease</gtr:title><gtr:parentPublicationTitle>Advances in Clinical Neuroscience and Rehabilitation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdebfe47aee08bc6677fa09ef0acda2f"><gtr:id>cdebfe47aee08bc6677fa09ef0acda2f</gtr:id><gtr:otherNames>Turner Martin R.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>mDYmCPSUeTZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>747F1A06-321E-48F2-8251-8135594FD1C8</gtr:id><gtr:title>Motor Neuron Disease: A Practical Manual</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/295cfd0ff1a5fed19fb01633133bc5c8"><gtr:id>295cfd0ff1a5fed19fb01633133bc5c8</gtr:id><gtr:otherNames>Talbot Kevin</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:isbn>978-0199547364</gtr:isbn><gtr:outcomeId>R4FxLfx7uMi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>074699A6-8778-4BDF-8208-4666BA868EF8</gtr:id><gtr:title>Mechanisms, models and biomarkers in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12643_23_23678877</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C1B0AB3-1E6A-4F71-A691-9D50319E9195</gtr:id><gtr:title>Myelin imaging in amyotrophic and primary lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/101bf71c975bd01cb8c440f2b356903e"><gtr:id>101bf71c975bd01cb8c440f2b356903e</gtr:id><gtr:otherNames>Kolind S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12643_23_23678852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90488EDE-5DB9-43CE-9AB0-183A0A42D306</gtr:id><gtr:title>Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/773c6071f403f6e92c200a057b518f06"><gtr:id>773c6071f403f6e92c200a057b518f06</gtr:id><gtr:otherNames>Douaud G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_12643_23_22075069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D57B6527-C479-49A9-AE8A-646BD6385187</gtr:id><gtr:title>Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77b34d0e3749b6ed66337c08edbfa8cc"><gtr:id>77b34d0e3749b6ed66337c08edbfa8cc</gtr:id><gtr:otherNames>Stagg CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>dQH4R1WBodx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18FC8ACF-6462-4BE0-883B-3B809D202C92</gtr:id><gtr:title>Amyotrophic lateral sclerosis and cancer: a register-based study in Sweden.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/204e8f8efdacdd48a69a974f86cddff4"><gtr:id>204e8f8efdacdd48a69a974f86cddff4</gtr:id><gtr:otherNames>Fang F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12643_23_23527497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7C1F49A-1C7C-4D40-A9DF-B280084DFE1B</gtr:id><gtr:title>A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcdc79518e85ab24b449aa0dc5ef6366"><gtr:id>dcdc79518e85ab24b449aa0dc5ef6366</gtr:id><gtr:otherNames>M?ller HP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56d2c61aa46d38.87946622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7370A1B-403A-4D33-81B6-2383E0C714EB</gtr:id><gtr:title>Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis?</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-180X</gtr:issn><gtr:outcomeId>pm_12643_23_22424125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03051BB6-2254-45D4-8D96-4BEC05BB024C</gtr:id><gtr:title>Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dac006df65aa6fc3664b1b55668fc4f"><gtr:id>9dac006df65aa6fc3664b1b55668fc4f</gtr:id><gtr:otherNames>Simpson CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>7C2027A0970</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62A15450-AA18-470E-933A-9CCFB8DEA90B</gtr:id><gtr:title>Neuroimaging in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Biomarkers in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1752-0363</gtr:issn><gtr:outcomeId>pm_12643_23_22731907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDD24911-BEC3-4782-A0EE-2A59427D4EDF</gtr:id><gtr:title>Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe424690789fe3b498adf4ad55c8999b"><gtr:id>fe424690789fe3b498adf4ad55c8999b</gtr:id><gtr:otherNames>Lu CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5675e3a58a574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B65F40B3-441A-4B1B-88E0-DA5BBD25AA97</gtr:id><gtr:title>Landmark Papers in Neurology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>546396b49ab638.69719399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>578B61B3-EBAC-4405-BE71-34A439815FF6</gtr:id><gtr:title>Amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/466f54e223c3415ea467756cdb3ba04f"><gtr:id>466f54e223c3415ea467756cdb3ba04f</gtr:id><gtr:otherNames>Kiernan MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>54637a54271100.91207453</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3057B733-05C2-41AE-B1DB-D4E561A278D6</gtr:id><gtr:title>Head and other physical trauma requiring hospitalisation is not a significant risk factor in the development of ALS.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>54637a5243ee56.60171457</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A502C475-7259-48C2-BBA5-3FEE13998380</gtr:id><gtr:title>Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fa71eb5bcb5dbba5a77cb5d30c89ec3"><gtr:id>9fa71eb5bcb5dbba5a77cb5d30c89ec3</gtr:id><gtr:otherNames>Oeckl P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>585d6ff0ba4d60.28154543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9681F0C3-3744-4A56-82DB-F4E5E9FB30D0</gtr:id><gtr:title>The sex ratio in amyotrophic lateral sclerosis: A population based study.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d24d309117afa93bba8fc18b9bf0c480"><gtr:id>d24d309117afa93bba8fc18b9bf0c480</gtr:id><gtr:otherNames>Manjaly ZR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-180X</gtr:issn><gtr:outcomeId>54637a52913c95.96448354</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7790160-CAFD-473E-8178-111D355E06D9</gtr:id><gtr:title>Management of sialorrhoea in motor neuron disease: a survey of current UK practice.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/302838d299ec84da92f209d22fc4b287"><gtr:id>302838d299ec84da92f209d22fc4b287</gtr:id><gtr:otherNames>Hobson EV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>pm_12643_23_23647474</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701923</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>